Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Lopalco

Showing results (151-160 of 221) with videos related to

Pageof 23
Sort By:
Rheumatology (Oxford, England)|February 18, 2026
The use of non-TNF targeted biologics in Behçet's Disease: Real-life data from the International AIDA Network Behçet's Disease RegistryGizem Sevik, Giuseppe Lopalco, Florenzo Iannone, et al.
Rheumatology (Oxford, England)|April 18, 2026
Phenotypic differences and treatment persistence in a large multicenter cohort of axial psoriatic arthritisGiuseppe Lopalco, Sergio Del Vescovo, Michele Maria Luchetti, et al.
Rheumatology (Oxford, England)|May 7, 2021
Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA RegistryJurgen Sota, Donato Rigante, Rolando Cimaz, et al.
Frontiers in Medicine|January 9, 2023
Canakinumab as first-line biological therapy in Still's disease and differences between the systemic and the chronic-articular courses: Real-life experience from the international AIDA registryAntonio Vitale, Valeria Caggiano, Maria Cristina Maggio, et al.
Annals of the Rheumatic Diseases|March 24, 2026
EULAR recommendations for the management of Behçet's syndrome: 2025 updateGulen Hatemi, Sofia Ramiro, Yesim Ozguler, et al.
Therapeutic Advances in Musculoskeletal Disease|September 16, 2021
Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA NetworkCarla Gaggiano, Donato Rigante, José Hernández-Rodríguez, et al.
Frontiers in Medicine|June 16, 2023
Axial spondyloarthritis in patients with recurrent fever attacks: data from the AIDA network registry for undifferentiated autoInflammatory diseases (USAIDs)Antonio Vitale, Valeria Caggiano, Isabel Silva, et al.
Therapeutic Advances in Musculoskeletal Disease|February 3, 2025
Efficacy and retention rate of secukinumab in psoriatic arthritis across different clinical phenotypes: insights from the Italian GISEA RegistryGiuseppe Lopalco, Maria Morrone, Fabiola Atzeni, et al.
Frontiers in Medicine|July 26, 2021
Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome-Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA NetworkAntonio Vitale, Laura Obici, Marco Cattalini, et al.
Rheumatology (Oxford, England)|August 4, 2025
Targeting axial and peripheral psoriatic arthritis: a retrospective observational study on the clinical relevance of upadacitinibGiuseppe Lopalco, Eleonora Celletti, Maria Morrone, et al.
Pageof 23

Showing results (151-160 of 221) with videos related to

Sort By:
Pageof 23
Rheumatology (Oxford, England)|February 18, 2026
The use of non-TNF targeted biologics in Behçet's Disease: Real-life data from the International AIDA Network Behçet's Disease RegistryGizem Sevik, Giuseppe Lopalco, Florenzo Iannone, et al.
Rheumatology (Oxford, England)|April 18, 2026
Phenotypic differences and treatment persistence in a large multicenter cohort of axial psoriatic arthritisGiuseppe Lopalco, Sergio Del Vescovo, Michele Maria Luchetti, et al.
Rheumatology (Oxford, England)|May 7, 2021
Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA RegistryJurgen Sota, Donato Rigante, Rolando Cimaz, et al.
Frontiers in Medicine|January 9, 2023
Canakinumab as first-line biological therapy in Still's disease and differences between the systemic and the chronic-articular courses: Real-life experience from the international AIDA registryAntonio Vitale, Valeria Caggiano, Maria Cristina Maggio, et al.
Annals of the Rheumatic Diseases|March 24, 2026
EULAR recommendations for the management of Behçet's syndrome: 2025 updateGulen Hatemi, Sofia Ramiro, Yesim Ozguler, et al.
Therapeutic Advances in Musculoskeletal Disease|September 16, 2021
Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA NetworkCarla Gaggiano, Donato Rigante, José Hernández-Rodríguez, et al.
Frontiers in Medicine|June 16, 2023
Axial spondyloarthritis in patients with recurrent fever attacks: data from the AIDA network registry for undifferentiated autoInflammatory diseases (USAIDs)Antonio Vitale, Valeria Caggiano, Isabel Silva, et al.
Therapeutic Advances in Musculoskeletal Disease|February 3, 2025
Efficacy and retention rate of secukinumab in psoriatic arthritis across different clinical phenotypes: insights from the Italian GISEA RegistryGiuseppe Lopalco, Maria Morrone, Fabiola Atzeni, et al.
Frontiers in Medicine|July 26, 2021
Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome-Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA NetworkAntonio Vitale, Laura Obici, Marco Cattalini, et al.
Rheumatology (Oxford, England)|August 4, 2025
Targeting axial and peripheral psoriatic arthritis: a retrospective observational study on the clinical relevance of upadacitinibGiuseppe Lopalco, Eleonora Celletti, Maria Morrone, et al.
Pageof 23